## WTW: Willis Towers Watson Public Limited Company - XLF: Financial Services

### Executive Summary

VALUE thesis: PEG 1.08 indicates fundamental undervaluation. Quality metrics strong (ROE 28%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($323.12)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Marsh & McLennan (NYSE:MMC) Reports Q3 CY2025 In Line With Expectations**
- Source: Finviz | 20251223T180817 | Neutral | Relevance: 62%
- Marsh & McLennan (NYSE:MMC) reported Q3 CY2025 results that met Wall Street's revenue expectations, with sales up 11.5% year-on-year to $6.35 billion. The professional services firm also beat non-GAAP profit estimates, reporting $1.85 per share, 4.1% above consensus. The company demonstrated solid growth in adjusted operating income and EPS, aligning with expectations despite a slight miss on Adjusted EBITDA.

**2. Brown & Brownâ€™s Deal Spree Has Investors Asking About The Payoff**
- Source: Finimize | 20251224T140812 | Neutral | Relevance: 55%
- Brown & Brown Inc. (NYSE: BRO) has pursued an aggressive acquisition strategy, leading to record revenues but also increased debt and integration costs, causing its stock to underperform the S&P 500. While its M&A engine drives top-line growth, organic growth has slowed and its valuation trades at a premium compared to peers. Investors are monitoring the company's ability to manage debt, integrate acquisitions effectively, and deliver on earnings to justify its higher multiple.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | Mizuho | $386 | $0 | 0% |
| 2025-12-12 | Wells Fargo | $356 | $362 | -2% |
| 2025-12-12 | Keefe, Bruyette | $375 | $373 | +1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | Mizuho | init | Outperform |
| 2025-12-12 | Wells Fargo | main | Overweight |
| 2025-12-12 | Keefe, Bruyette | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 27 ($0.23M) |
| Sells | 7 ($0.24M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 55.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.9%)
- Blackrock Inc.: 9.7% (-4.7%)
- Massachusetts Financ: 6.5% (-0.9%)
- Harris Associates L.: 4.5% (+13.4%)
- State Street Corpora: 4.5% (-0.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.08 suggests fair value with growth premium. Quality metrics strong (ROE 28%, margin 22%). Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $32.6B |
| Beta | 0.64 |
| 52W Range | $292.97 - $352.79 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.08 |
| Forward P/E | 17.3 |
| Current P/E | 19.7 |
| YoY Growth | 13.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.2% to 1.8% (-1.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.2pp (needs >4.0% for momentum thesis). MRS_5 (-0.3%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.36), confirming momentum. OFD pattern: +SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.83% (CS: 74) | Neutral |
| RSI_14 | 64.9 | Neutral |
| MACD Histogram | 1.36 | Bullish |
| vs SMA20 | 1.030x | Above |
| vs SMA50 | 1.033x | Above |
| vs SMA200 | 1.042x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $334.52
- **Stop Loss:** $323.12 (3.4% risk)
- **Target:** $357.32 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 126
- **Position Value:** $42,149.52
- **Portfolio %:** 42.15%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-02-05 (Est: $7.95)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.05 | $3.07 | +0.7% |
| 2025Q2 | $2.60 | $2.86 | +10.2% |
| 2025Q1 | $3.19 | $3.13 | -1.8% |
| 2024Q4 | $8.03 | $8.13 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*